Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir H Moussa

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Water and Health|January 23, 2008
Identification of the sources of Escherichia coli in a watershed using carbon-utilization patterns and composite data setsSamir H Moussa, Rene D Massengale
Journal of Bacteriology|April 8, 2014
Genetic dissection of T4 lysisSamir H Moussa, Jessica L Lawler, Ry Young
Antimicrobial Agents and Chemotherapy|April 3, 2024
Characterization of <i>Acinetobacter baumannii-calcoaceticus</i> complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)Alita A Miller, Samir H Moussa, Sarah M McLeod
Research in Microbiology|November 24, 2018
Role of the Klebsiella pneumoniae TolC porin in antibiotic effluxRamkumar Iyer, Samir H Moussa, Ruben Tommasi, et al.
ACS Infectious Diseases|November 30, 2018
Titrating Levels of TolC in E. coli: A Sensitive Approach to Quantifying EffluxRamkumar Iyer, Samir H Moussa, Ruben Tommasi, et al.
Antimicrobial Agents and Chemotherapy|January 29, 2020
<i>In Vitro</i> Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-<i>calcoaceticus</i> Complex Isolates Collected Globally in 2016 and 2017Sarah M McLeod, Samir H Moussa, Meredith A Hackel, et al.
ACS Infectious Diseases|December 21, 2017
Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant PorinRamkumar Iyer, Samir H Moussa, Thomas F Durand-Réville, et al.
ACS Infectious Diseases|December 9, 2020
Ceftazidime-Avibactam Resistance Mutations V240G, D179Y, and D179Y/T243M in KPC-3 β-Lactamase Do Not Alter Cefpodoxime-ETX1317 SusceptibilityAdam B Shapiro, Samir H Moussa, Nicole M Carter, et al.
Protein Science : a Publication of the Protein Society|March 6, 2012
Protein determinants of phage T4 lysis inhibitionSamir H Moussa, Vladimir Kuznetsov, Tram Anh T Tran, et al.
Frontiers in Microbiology|August 5, 2021
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of <i>Acinetobacter</i> Infections in Combination With SulbactamAdam B Shapiro, Samir H Moussa, Sarah M McLeod, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Water and Health|January 23, 2008
Identification of the sources of Escherichia coli in a watershed using carbon-utilization patterns and composite data setsSamir H Moussa, Rene D Massengale
Journal of Bacteriology|April 8, 2014
Genetic dissection of T4 lysisSamir H Moussa, Jessica L Lawler, Ry Young
Antimicrobial Agents and Chemotherapy|April 3, 2024
Characterization of <i>Acinetobacter baumannii-calcoaceticus</i> complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)Alita A Miller, Samir H Moussa, Sarah M McLeod
Research in Microbiology|November 24, 2018
Role of the Klebsiella pneumoniae TolC porin in antibiotic effluxRamkumar Iyer, Samir H Moussa, Ruben Tommasi, et al.
ACS Infectious Diseases|November 30, 2018
Titrating Levels of TolC in E. coli: A Sensitive Approach to Quantifying EffluxRamkumar Iyer, Samir H Moussa, Ruben Tommasi, et al.
Antimicrobial Agents and Chemotherapy|January 29, 2020
<i>In Vitro</i> Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-<i>calcoaceticus</i> Complex Isolates Collected Globally in 2016 and 2017Sarah M McLeod, Samir H Moussa, Meredith A Hackel, et al.
ACS Infectious Diseases|December 21, 2017
Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant PorinRamkumar Iyer, Samir H Moussa, Thomas F Durand-Réville, et al.
ACS Infectious Diseases|December 9, 2020
Ceftazidime-Avibactam Resistance Mutations V240G, D179Y, and D179Y/T243M in KPC-3 β-Lactamase Do Not Alter Cefpodoxime-ETX1317 SusceptibilityAdam B Shapiro, Samir H Moussa, Nicole M Carter, et al.
Protein Science : a Publication of the Protein Society|March 6, 2012
Protein determinants of phage T4 lysis inhibitionSamir H Moussa, Vladimir Kuznetsov, Tram Anh T Tran, et al.
Frontiers in Microbiology|August 5, 2021
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of <i>Acinetobacter</i> Infections in Combination With SulbactamAdam B Shapiro, Samir H Moussa, Sarah M McLeod, et al.
Pageof 3